Amylyx Pharmaceuticals (AMLX) Treasury Shares (2021 - 2026)

Amylyx Pharmaceuticals' Treasury Shares history runs 6 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Treasury Shares rose 23.92% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 23.92% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, up 23.15% from the prior year.
• Treasury Shares improved to $3.9 million in Q1 2026 per AMLX's latest filing, from $2.7 million in the prior quarter.
• Across five years, Treasury Shares topped out at $3.9 million in Q1 2026 and bottomed at $596709.0 in Q1 2022.
• The 5-year median for Treasury Shares is $2.1 million (2024), against an average of $1.9 million.
• Across the five-year window, Treasury Shares slumped 98.0% in 2022 and surged 174.08% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $740297.0 in 2022, then soared by 50.28% to $1.1 million in 2023, then surged by 98.91% to $2.2 million in 2024, then advanced by 23.15% to $2.7 million in 2025, then jumped by 44.33% to $3.9 million in 2026.
• Per Business Quant, the three latest AMLX Treasury Shares figures stand at $3.9 million (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025).